Jane Street’s Syndax Pharmaceuticals SNDX Stock Holding History

Jane Street’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$378K	Sell	16,200 -17,100	-51%	-$372K	﹤0.01%	8690
2025 Q4	$700K	Sell	33,300 -6,400	-16%	-$112K	﹤0.01%	6962
2025 Q3	$611K	Buy	39,700 +5,500	+16%	+$72K	﹤0.01%	7420
2025 Q2	$320K	Buy	34,200 +13,600	+66%	+$150K	﹤0.01%	7735
2025 Q1	$253K	Buy	+20,600	New	+$291K	﹤0.01%	8091
2024 Q4	–	Sell	-39,600	Closed	-$762K	–	10503
2024 Q3	$762K	Buy	+39,600	New	+$818K	﹤0.01%	6434
2024 Q2	–	Sell	-45,200	Closed	-$1.08M	–	10133
2024 Q1	$1.08M	Buy	+45,200	New	+$1.01M	﹤0.01%	5283
2023 Q4	–	Sell	-111,900	Closed	-$1.62M	–	9757
2023 Q3	$1.62M	Buy	+111,900	New	+$2.12M	﹤0.01%	4384
2020 Q3	–	Sell	-25,000	Closed	-$371K	–	7862
2020 Q2	$371K	Buy	+25,000	New	+$381K	﹤0.01%	5515

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Jane Street's SNDX Position: Q1 2026 in Review

Jane Street reduced its Syndax Pharmaceuticals (SNDX) stake by 55% in Q1 2026, selling an estimated $8.98M and leaving 335,531 shares worth $7.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Jane Street first reported a position in SNDX in Q2 2020 and has held it in 18 quarters since. The position peaked at $15.7M in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Jane Street held 335,531 shares of Syndax Pharmaceuticals worth $7.84M as of Q1 2026.
Jane Street sold 413,389 Syndax Pharmaceuticals shares in Q1 2026, an estimated $8.98M.
Syndax Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2848 holding.
Jane Street first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
Jane Street's Syndax Pharmaceuticals position peaked at $15.7M in Q4 2025.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.